Alnylam Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. 

CEO
Yvonne L. Greenstreet
CEOYvonne L. Greenstreet
Employees
2,230
Employees2,230
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2002
Founded2002
Employees
2,230
Employees2,230

ALNY Key Statistics

Market cap
61.36B
Market cap61.36B
Price-Earnings ratio
1.97K
Price-Earnings ratio1.97K
Dividend yield
Dividend yield
Average volume
1.07M
Average volume1.07M
High today
$473.50
High today$473.50
Low today
$464.45
Low today$464.45
Open price
$468.76
Open price$468.76
Volume
34.68K
Volume34.68K
52 Week high
$495.55
52 Week high$495.55
52 Week low
$205.87
52 Week low$205.87

Stock Snapshot

The current Alnylam Pharmaceuticals(ALNY) stock price is $464.45, with a market capitalization of 61.36B. The stock trades at a price-to-earnings (P/E) ratio of 1968.76.

During the trading session on 2025-12-05, Alnylam Pharmaceuticals(ALNY) shares reached a daily high of $473.50 and a low of $464.45. At a current price of $464.45, the stock is 0.0% higher than the low and still -1.9% under the high.

Trading volume for Alnylam Pharmaceuticals(ALNY) stock has reached 34.68K, versus its average volume of 1.07M.

Over the past 52 weeks, Alnylam Pharmaceuticals(ALNY) stock has traded between a high of $495.55 and a low of $205.87.

Over the past 52 weeks, Alnylam Pharmaceuticals(ALNY) stock has traded between a high of $495.55 and a low of $205.87.

ALNY News

Simply Wall St 24h
Alnylam Pharmaceuticals: Is the Stock’s Recent Surge Justified by Its Valuation?

Alnylam Pharmaceuticals (ALNY) has quietly extended its strong run, with the stock up about 12% over the past month and nearly doubling over the past year, invi...

Alnylam Pharmaceuticals: Is the Stock’s Recent Surge Justified by Its Valuation?
Simply Wall St 4d
Spotlight On Alnylam Pharmaceuticals And 2 Other Stocks Possibly Trading Below Fair Value

As the U.S. stock market wraps up a strong week, with major indices like the S&P 500 and Dow Jones Industrial Average extending their winning streaks, investors...

Spotlight On Alnylam Pharmaceuticals And 2 Other Stocks Possibly Trading Below Fair Value
Nasdaq 6d
ALNY Quantitative Stock Analysis

Below is Validea's guru fundamental report for ALNYLAM PHARMACEUTICALS, INC. (ALNY). Of the 22 guru strategies we follow, ALNY rates highest using our Twin Mome...

ALNY Quantitative Stock Analysis

Analyst ratings

68%

of 31 ratings
Buy
67.7%
Hold
29%
Sell
3.2%

More ALNY News

Simply Wall St 6d
The Bull Case For Alnylam Pharmaceuticals Could Change Following Raised Sales Guidance for Vutrisiran

Earlier this quarter, Carillon Tower Advisers highlighted Alnylam Pharmaceuticals after the company's launch of vutrisiran for transthyretin amyloidosis surpass...

The Bull Case For Alnylam Pharmaceuticals Could Change Following Raised Sales Guidance for Vutrisiran

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.